Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 second-quarter earnings
Illustration of people examining large charts and graphs

What you need to know about Johnson & Johnson’s 2022 second-quarter earnings

Check out this infographic breakdown of the company’s second-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

q1-2022-quarterlyearnings-0422.png

This morning, Johnson & Johnson shared its second-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“We are proud to have delivered on the robust operational guidance that we set forth at the beginning of the year, as we’ve continued to advance breakthrough innovation and foster patient access to make a positive impact across many areas of healthcare,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Johnson & Johnson is strongly positioned to continue making progress on our business priorities, including the creation of the New Consumer Health Company, to deliver both near- and long-term value to all of our Credo stakeholders.”

For more details about the company’s 2022 second-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


Johnson & Johnson Q2 2022 earnings infographic

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.